LA
SEEL

LM Advisors’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

LM Advisors’s Portfolio SEEL Stock Details SEEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1
Closed -$115 – 733
2023
Q4 		$115 Buy
+1
New +$492 ﹤0.01% 725

Other funds holding SEEL

WE
Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MWM
Modera Wealth Management Westwood, New Jersey $8.34B AUM 19.68% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SFWC
Strategic Family Wealth Counselors Fairfield, New Jersey $381M AUM 21.36% 1-Year Est. Return

LM Advisors's SEEL Position: Q1 2024 in Review

LM Advisors sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q1 2024, closing a stake of 1 share — an estimated $115 sold.

LM Advisors first reported a position in SEEL in Q4 2023 and held it in 1 quarter. The position peaked at $115 in Q4 2023. 29 funds tracked by Wall St. Rank hold SEEL as of Q1 2024.

  • LM Advisors reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • LM Advisors sold 1 Seelos Therapeutics, Inc. Common Stock share in Q1 2024, an estimated $115.
  • LM Advisors first reported a position in Seelos Therapeutics, Inc. Common Stock in Q4 2023 and held it in 1 quarter.
  • LM Advisors's Seelos Therapeutics, Inc. Common Stock position peaked at $115 in Q4 2023.
  • 29 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q1 2024.

Based on LM Advisors's 13F filing for Q1 2024, filed 15 May 2024.